Publications

Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke.

Kuipers, A., Moll, G.N., Levy, A., Krakovsky, M., Franklin, R. Peptides 123, 170193

Genetically Encoded Libraries of Constrained Peptides.

Bosma, T., Rink, R., Moosmeier, M.A., Moll, G.N. Chembiochem 20, 1754-1758

Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.

Kuipers, A., Moll, G.N., Wagner, E., Franklin, R. Peptides 112, 78-84.

Phage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein.

Urban J.U., Moosmeier, M.A., Aumüller, T., Thein, M., Bosma, T., Rink, R., Groth, K., Zulley, M., Siegers, K., Tissot, K., Moll, G.N., Prassler, J.Nature Comm. 2017 Nov 15;8(1):1500
Semi-microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like-peptide-1.

Kuipers, A., de Vries, L., de Vries, M.P., Rink, R., Bosma, T., Moll, G.N. Peptides 91, 33-39.
Mutagenesis of nisin's leader peptide proline strongly modulates export of precursor nisin.

Plat, A., Kuipers, A., Crabb, J., Rink, R., Moll, G.N. Antonie Van Leeuwenhoek 110, 321-330.
Mechanistic aspects of lanthipeptide leaders.

Plat, A., Kuipers, A., Rink, R., Moll, G.N. Curr. Protein Pept. Sci. 14, 85-96.

GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.

Carlucci, G., Kuipers, A., Ananias, H.J., de Paula Faria, D., Dierckx, R.A., Helfrich, W., Rink, R., Moll, G.N., de Jong IJ, Elsinga PH. Peptides 67, 45-54.

The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction.

Durik, M., van Veghel, R., Kuipers, A., Rink, R, Haas, Jimoh Akanbi, M., Moll, G., Danser, A.H., Roks, A.J. Int J Hypertens 2012, 536426.
Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.

Wagenaar, G.T., Laghmani, E.H., Fidder, M., Sengers, R.M., de Visser, Y.P., de Vries, L., Rink, R., Roks, A,J., Folkerts, G., Walther, F.J.

Bacterial display and screening of posttranslationally thioether-stabilized peptides.

Bosma, T., Kuipers, A., Bulten, E., de Vries, L., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 77, 6794-801.

To protect peptide pharmaceuticals against peptidases.

Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S.A., Haas-Jimoh-Akanbi, M., Moll, G.N. Pharmacol. Toxicol. Methods. 61, 210–218

Angiotensin-(1-7) with thioether-bridge: an ACE-resistant, potent Ang-(1-7) analogue

Kluskens, L.D., Nelemans, S.A., Rink, R., de Vries, L., Meter-Arkema, A., Wang, Y., Walther, T., Kuipers, A., Moll, G. N., and Haas, M. J. Pharmacol. Exper. Ther. 328, 849-854
A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges.

Moll, G.N. Kuipers, A., de Vries, L., Bosma, T., Rink, R. Drug Discov Today: Technol. doi:10.1016/j.ddtec.2009.03.
Translocation of a thioether-bridged azurin peptide fragment via the sec pathway in Lactococcus lactis

Kuipers, A., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 75, 3800-3802

You are here